Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/199168
Type: Artigo de periódico
Title: Cumulative Doses Of Radioiodine In The Treatment Of Differentiated Thyroid Carcinoma: Knowing When To Stop.
Author: Martins-Filho, Raul
Ward, Laura S
Amorim, Barbara J
Santos, Allan O
Lima, Mariana C L de
Ramos, Celso D
Matos, Patricia S
Assumpção, Lígia V M
Camargo, Edwaldo E
Etchebehere, Elba C S C
Abstract: Evaluate the efficacy of cumulative doses (CDs) of 131I-iodide therapy (RIT) in differentiated thyroid cancer (DTC). The probability of progressive disease according to CDs was evaluated in patients < 45 years old and > 45 years old and correlated to tumor-node-metastasis (TNM), thyroglobulin values, histological types and variants, age, and zduration of the disease. At the end of a follow-up period of 69 ± 56 months, 85 out of 150 DTC patients submitted to fixed doses RIT had no evidence of disease, 47 had stable disease and 18 had progressive disease. Higher CDs were used in the more aggressive variants (p < 0.0001), higher TNM stages (p < 0.0001), and follicular carcinomas (p = 0.0034). Probability of disease progression was higher with CDs > 600 mCi in patients > 45 years old and with CDs > 800 mCi in patients < 45 years. Although some patients may still respond to high CDs, the impact of further RIT should be carefully evaluated and other treatment strategies may be warranted.
Subject: Carcinoma, Papillary
Disease Progression
Dose-response Relationship, Radiation
Epidemiologic Methods
Female
Humans
Iodine Radioisotopes
Male
Middle Aged
Thyroid Neoplasms
Treatment Outcome
Citation: Arquivos Brasileiros De Endocrinologia E Metabologia. v. 54, n. 9, p. 807-12, 2010-Dec.
Rights: aberto
Identifier DOI: 
Address: http://www.ncbi.nlm.nih.gov/pubmed/21340173
Date Issue: 2010
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
pmed_21340173.pdf1.15 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.